Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 9mogamulizumab 6Biopsy 6fludarabine 5fludarabine phosphate 4Specimen Handling 4Immunoglobulin G 4Disulfides 4Brentuximab Vedotin 4ruxolitinib 3romidepsin 3pembrolizumab 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Etoposide 3Busulfan 3hypericin 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Nivolumab 2Melphalan 2Depsipeptides 2tofacitinib 1thymoglobulin 1tazemetostat 1talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Lactones × 1 year × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡